Acetylcholine was the first neurotransmitter anyone identified, and it is built from a nutrient that has to come in through the diet. This is the path from a meal to a released signalling molecule, and the point on that path where the form of choline stops being interchangeable.
The first neurotransmitter ever identified
In 1921 Otto Loewi stimulated the vagus nerve of an isolated frog heart, collected the fluid around it, and applied that fluid to a second heart. The second heart slowed. Something chemical, not merely electrical, had carried the signal.
He called it Vagusstoff. It was acetylcholine, and it earned Loewi a share of the 1936 Nobel Prize in Physiology or Medicine with Henry Dale.
A century later it remains one of the best-characterised molecules in physiology, which is worth keeping in mind when reading anything that treats it as exotic.
Where it works in the body
At the junction with muscle
Every voluntary muscle contraction in the body is triggered by acetylcholine crossing the gap between a motor nerve and a muscle fibre. This is not a subtle role.
In the parasympathetic system
It is the main transmitter of the rest-and-digest branch of the autonomic nervous system — slowing the heart, driving digestion and glandular secretion.
In the brain
A set of cholinergic cells in the basal forebrain projects widely across the cortex and into the hippocampus. Those projections are the reason acetylcholine appears in research on attention and on the encoding of new memories.
How a molecule of it gets made
One reaction, two inputs. An enzyme called choline acetyltransferase joins choline to an acetyl group carried by acetyl-CoA, a product of ordinary energy metabolism.
Acetyl-CoA is abundant. Choline has to arrive from somewhere, and that asymmetry is the entire reason choline gets discussed alongside attention at all.
How it gets taken apart
An enzyme, acetylcholinesterase, splits the molecule almost immediately after release. This is a feature: a signal that did not stop would be useless.
Much of the choline released by that split is recaptured by a dedicated transporter on the nerve terminal and used again. The system recycles, which is one reason supply is not a simple story.
Where the choline comes from
Mostly from food
The liver makes some phosphatidylcholine on its own, but not enough to cover the body's choline requirement. Choline is classed as an essential nutrient, which is the technical way of saying the diet has to supply it.
Mostly as phosphatidylcholine
Very little dietary choline arrives as free choline. Most of it comes bound into phosphatidylcholine, a phospholipid that is a structural component of every cell membrane.
The pathway that converts one into the other
The route from free choline to membrane phospholipid runs in three steps, and it is worth naming because a popular supplement ingredient is a copy of the intermediate.
- Choline is phosphorylated to phosphocholine.
- Phosphocholine is combined with a cytidine carrier to make CDP-choline.
- CDP-choline is joined to a lipid backbone, producing phosphatidylcholine.
Citicoline, sold as a nootropic, is that second intermediate. Alpha-GPC is what phosphatidylcholine breaks down into. The supplement aisle is largely selling points along one pathway.
Why intake is a live question
Habitual choline intake in the United States remains below the Adequate Intake of 550 mg a day for adult men and 425 mg for adult women (Trujillo-Gonzalez et al., American Journal of Clinical Nutrition, 2026; US adults).
In one study of older adults, only 10% of participants met the Adequate Intake for choline (Suzuki et al., Journal of Food Composition and Analysis, 2025; n=203, aged 65 and over).
Neither finding says anything about how any particular person feels. They describe intake distributions in populations, which is all a dietary survey can describe.
Why the form changes what happens next
First, the argument that does not work
It is tempting to assume the researched forms simply carry more choline. They do not, and the arithmetic is easy to check.
Choline itself has a molecular weight of about 104. Choline bitartrate weighs about 253, so choline is roughly 41% of it. Alpha-GPC weighs about 257, so choline is roughly 40% of it. Per milligram, the two deliver almost the same amount of choline.
Anyone arguing for a form on the grounds of choline content is arguing from a number that does not separate them.
Second, the argument that does
What separates them is what has been measured. In healthy adults, the trial evidence for choline bitartrate is sparse. The one published study gave a single 1,650 mg dose to twenty postmenopausal women and found no working-memory performance difference against placebo, though brain activation did change (Dumas et al., 2026; n=20). A single trial of twenty people is not dispositive, but it is the only direct test available, and it is not a positive one.
That last clause matters. The honest reading is "has not shown the benefit", not "does not reach the brain" — the two are different claims and only one of them is supported.
Third, what is claimed for alpha-GPC, stated at its actual strength
Review-level evidence describes alpha-GPC as able to cross the blood–brain barrier (Putri et al., Neuropsychiatric Disease and Treatment, 2026; narrative review). A narrative review is a summary of other people's work, not a trial, and it is quoted here at that weight and no more.
Research on alpha-GPC in healthy adults has run at single doses of roughly 250 to 630 mg. Higher figures appear in marketing, but those trials were run in people with diagnosed cognitive impairment — a different population, and not transferable. Both sides of that are in how much alpha-GPC the research actually used, and the form comparison is in alpha-GPC vs choline bitartrate.
The three forms side by side
| Form | Where it sits on the pathway | Choline by weight | What has been measured in healthy adults |
|---|---|---|---|
| Choline bitartrate | Free choline, paired with tartaric acid | About 41% | No working-memory performance difference against placebo at a single 1,650 mg dose (Dumas et al., 2026; n=20) |
| Citicoline (CDP-choline) | The middle intermediate | Lower per milligram — the molecule carries a cytidine group as well | Researched separately; frequently branded |
| Alpha-GPC | A breakdown product of phosphatidylcholine | About 40% | Trials have run at single doses of roughly 250 to 630 mg |
Four things this does not mean
Acetylcholine is not a fuel, and choline is not a fuel. Supply and demand at a nerve terminal are not the same as a tank being filled.
More is not linearly better. Choline has an upper intake level, and very high intakes are associated with a fishy body odour caused by a bacterial breakdown product.
Gut bacteria also convert some choline into a compound that has been studied in relation to cardiovascular risk. That work is unsettled, and it is a reason for care rather than alarm.
And attention is not one molecule. Dopamine, noradrenaline and several other systems are involved, and any account that names a single chemical is a simplification for the sake of a sentence.
Mechanism is not evidence
Every step above is well established, and none of it proves that swallowing choline does anything in particular.
A plausible pathway explains why a trial might be worth running. It does not stand in for the trial, and a great deal of supplement copy relies on the reader not noticing the substitution.
What all of this reduces to, on a label
One word, inside the parentheses: alpha-GPC, citicoline or choline bitartrate. Three separately researched compounds on one shelf at similar prices, distinguished by a term almost nobody reads.
Finding it takes about ten seconds, using the sequence in how to read a Supplement Facts panel in about sixty seconds.
Where we stand
Weal Focus uses alpha-GPC at 300 mg, printed on the panel with the form named. That is a statement about which compound is in the capsule and what quantity of it, and it is checkable against any other pack on the same shelf.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Sources for the claims and figures on this page, with the population studied in each, are on our citations page.